InVivo Therapeutics presented complete six-month results from its INSPIRE study, which was temporarily halted after three patients died during the study last year.
LivaNova topples Wall Street consensus on sales and EPS in its first quarter, but sees dip in shares.
Nearly 11 years after being spun off from Medtronic, Inspire Medical is going public through a $75 million IPO.
Boston Scientific received FDA approval for the Vercise technology to treat Parkinson's disease in December of 2017, based on the results of the INTREPID trial data.
Cardiology societies recently updated guidelines on the management of adults at risk for sudden cardiac death to include the use of a subcutaneous implantable cardioverter-defibrillator (S-ICD). But are the latest recommendations having unintended consequences?
Emboline, an emerging medical device company, has raised $10 million in a Series B round to get its embolic protection technology on the market in Europe.
Robotics, pricing concerns, and the prevalence of more procedures being performed at ambulatory centers are some of the hot topics in the orthopedics market.
Intersect ENT brings its fourth commercial product, the Sinuva Sinus implant, to market to treat nasal polyp disease.
SetPoint Medical launches 15-patient pilot trial for its miniaturized vagus nerve stimulation device to treat RA.
Edwards Lifesciences plans to submit additional data for the Sapien 3 Ultra valve before it files for CE mark, causing a slight delay in the product getting to the market.
Colibri has treated the first two patients in a feasibility study and cites Edwards Lifesciences as its main competition in the TAVR market.
FDA gave the company the green light to end a trial of its LAP-BAND System early, saving the company more than $5 million.
FDA Commissioner Scott Gottlieb updated the public regarding the agency's ongoing post-market review of the controversial birth control device, but patient advocacy group Essure Problems says the commissioner's words are just another letdown.